3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
10
Thoracic
4
Dermatologic
3
Head & Neck
2
Gastrointestinal
2
Other solid neoplasm
1
Breast
1
Conditions
Breast Neoplasms
23
Carcinoma, Non-Small-Cell Lung
8
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Lung Neoplasms
4
Breast Neoplasms, Male
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Mesothelioma
2
Melanoma
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Sarcoma
1
Salivary Gland Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
NSCLC
1
Mesothelioma, Malignant
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Fallopian Tube Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
18
Nivolumab
12
atezolizumab
5
Ipilimumab
4
Cyclophosphamide
4
fludarabine
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Docetaxel
3
Carboplatin
3
spartalizumab
2
cabozantinib
2
avelumab
2
aldesleukin
2
Specimen Handling
2
Interleukin-2
2
Immunoglobulin G
2
zanidatamab
1
veliparib
1
trastuzumab deruxtecan
1
tislelizumab
1
temsirolimus
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
regorafenib
1
poly ICLC
1
pemigatinib
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Pemetrexed
×
Breast
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts